ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Sjogren’s syndrome"

  • Abstract Number: 2551 • 2014 ACR/ARHP Annual Meeting

    Presence of Germinal Centers at Baseline Is Associated with Clinical Response of Glandular Essdai Domain after Abatacept Treatment in Primary Sjogren’s Syndrome

    Erlin A. Haacke1, Frans G.M. Kroese2, Petra M. Meiners3, Bert van der Vegt1, Arjan Vissink4, Fred K.L. Spijkervet3 and Hendrika Bootsma2, 1Pathology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 3Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 4Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands

    Background/Purpose: Abatacept inhibits the costimulatory interaction of T-lymphocytes and antigen-presenting cells. Treatment of early and active primary Sjögren's Syndrome (pSS) with abatacept decreases disease activity.…
  • Abstract Number: 985 • 2014 ACR/ARHP Annual Meeting

    Labial Salivary Gland Antibody-Secreting Cell Specificity and Characteristics in Sjögren’s Patients

    Kristi A. Koelsch1, Jacen Maier-Moore2, Kenneth Smith3, Christopher Lessard3, Astrid Rasmussen4, Biji Kurien3, Umesh Deshmukh3, A. Darise Farris3, Judith A. James5, Kathy L. Sivils4, R. Hal Scofield6 and Mark Coggeshall7, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, 2Dept. of Clinical Laboratory Science, University of Texas at El Paso, El Paso, TX, 3Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 7Immunobiology and Cancer Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose Studies were approved by the OMRF and the University of Oklahoma Health Sciences Center Institutional Review Boards. Samples and data were obtained from 9…
  • Abstract Number: 2977 • 2014 ACR/ARHP Annual Meeting

    Distinct Serum Protein Signature and Novel Biomarkers of primary Sjogren’s Syndrome Revealed by comprehensive High-Throughput Proteomic Analysis

    Ayumi Nishikawa1, Katsuya Suzuki2, Yoshiaki Kassai3, Yuumi Gotou4, Takahiro Miyazaki3, Maiko Takiguchi5, Masaru Takeshita1, Atsuko Murota2, Rimpei Morita6, Akihiko Yoshimura6 and Tsutomu Takeuchi2, 1Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, 4Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Tokyo, Tokyo, Japan, 5Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Tokyo, Japan, 6Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: The EULAR SS Disease Activity Index (ESSDAI) is currently used as an objective evaluation method of clinical disease activity in clinical research into primary…
  • Abstract Number: 2550 • 2014 ACR/ARHP Annual Meeting

    Impaired Speckle Tracking As a Marker of Subclinical Left Ventricular Dysfunction in Patients Affected By Primary Sjögren’s Syndrome

    Fabiola Atzeni1, Stefano Galaverna2, Chiara Colombo2, Luigi Gianturco2, Laura Boccassini1, Piercarlo Sarzi-Puttini1 and Maurizio Turiel2, 1Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, 2Cardiology Unit, IRCCS-Galeazzi Orthopedic Institute,, Milan, Italy

    Background/Purpose Primary Sjögren’s syndrome (pSS) is a common chronic autoimmune disease that particularly affects the salivary and lachrymal glands, and leads to dry eyes and…
  • Abstract Number: 534 • 2014 ACR/ARHP Annual Meeting

    Serum Biomarkers of Inflammation and Fibrosis in Advancing Diagnosis, Prognosis and Treatment of  Anti-Ro Associated Congenital Heart Block

    Amit Saxena1, Peter M. Izmirly2, Sung Won Han3, Andrew Markham4, Robert M. Clancy5 and Jill P. Buyon5, 1Rheumatology, New York University School of Medicine, New York, NY, 2Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 3Department of Population Health, New York University School of Medicine, New York, NY, 4Medicine, New York University School of Medicine, New York, NY, 5Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose Women with Sjogren’s Syndrome (SS) and anti-Ro antibodies face the risk of a pregnancy complicated by fetal congenital heart block (CHB).  Identification of maternal…
  • Abstract Number: 2979 • 2014 ACR/ARHP Annual Meeting

    Nucleic Acid Sensing Receptors TLR7, RIG-I and MDA5 Collaborate in Driving the Systemic IFN Signature and Amplify the Pathogenic Loop: Potential New Targets for Therapy in Primary Sjogrens Syndrome

    Naomi I Maria1, Cornelia G. van Helden-Meeuwsen1, Eline C. Steenwijk1, Arne S. IJpma2, Wouter Beumer1, Zana Brkic1, Virgil A. Dalm1, Paul L. van Daele1, P. Martin van Hagen1, Peter J. van der Spek2, Hemmo A. Drexhage1 and Marjan A. Versnel1, 1Erasmus Medical Center, Immunology, Rotterdam, Netherlands, 2Erasmus Medical Center, Bioinformatics, Rotterdam, Netherlands

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by autoantibodies targeting RNA-associated antigens, anti-SSA/SSB. The IFN-signature is present in over half of…
  • Abstract Number: 2546 • 2014 ACR/ARHP Annual Meeting

    Metabolic Disorders Causing Fatigue in Sjogren’s Syndrome

    Lakshmanan Suresh1, Julian Ambrus2, Long Shen3 and Sahana Vishwanath4, 160 Pineview Drive, State University of New York/Buffalo, Buffalo, NY, 2100 High St., University Of Buffalo, Buffalo, NY, 3Department of Medicine, SUNY at Buffalo, Buffalo, NY, 4Medicine, SUNY- Buffalo, buffalo, NY

    Background/Purpose Sjogren’s syndrome (SS) is a complex disorder involving both the innate and immune system. Fatigue is a common feature of the disease. Mitochondrial dysfunction…
  • Abstract Number: 533 • 2014 ACR/ARHP Annual Meeting

    Predictive Significance of CCL21 and CXCL13 Levels in the Minor Salivary Glands of Patients with Sjögren’s Syndrome

    Kyung-Eun Lee1, Dong-Jin Park1 and Shin-Seok Lee2, 1Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, 2Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea

    Background/Purpose Chemokines, which control inflammatory cell migration, have been shown to play important roles in the inflammatory processes associated with Sjögren’s Syndrome (SS). CCL21 and…
  • Abstract Number: 2981 • 2014 ACR/ARHP Annual Meeting

    Prognostic Value of the Complex P2X7 Receptor-Inflammasome in Patients with Primary Sjögren’s Syndrome at Lymphoma Risk

    Chiara Baldini1, Eleonora Santini2, Chiara Rossi2, Francesca Sernissi1, Daniela Martini1, Alessia Gallo3, Valentina Donati2, Nicoletta Luciano1, Francesco Ferro1, Illias Alevizos4, Anna Solini2 and Stefano Bombardieri5, 1University of Pisa, Rheumatology Unit, Pisa, Italy, 2Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, 3Sjogren's Clinic, NIDCR, Bethesda, MD, 4NIDCR, Bethesda, MD, 5Rheumatology Unit, University of Pisa, Pisa, Italy

    Background/Purpose: Pro-inflammatory P2X7-receptor has been recently implicated in the pathogenesis of primary Sjögren’s syndrome (pSS), suggesting that it may be involved in the initiation and…
  • Abstract Number: 2544 • 2014 ACR/ARHP Annual Meeting

    How Does a Younger Age at the Onset of Sjögren’s Syndrome (pSS) Influence the Clinical Presentation and the Clinical Course of the Disease?

    Chiara Baldini1, Luca Quartuccio2, Elena Bartoloni-Bocci3, Roberta Priori4, Francesco Carubbi5, Alessia Alunno3, Roberto Gerli3, Guido Valesini4, Salvatore De Vita2 and Stefano Bombardieri6, 1University of Pisa, Rheumatology Unit, Pisa, Italy, 2Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, 3Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, 4Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, 5Rheumatology Clinic, University of L'Aquila, L'Aquila, Italy, 6Rheumatology Unit, University of Pisa, Pisa, Italy

    Background/Purpose: (1) To analyze the clinical presentation and the clinical course of Sjögren’s Syndrome (pSS) in Caucasian patients with an “early-onset” pSS and (2) to compare…
  • Abstract Number: 532 • 2014 ACR/ARHP Annual Meeting

    Adipose Tissue Is Prominent in Salivary Glands of Sjögren’s Syndrome Patients and Appears to Influence the Autoimmune Microenvironment in These Organs

    Kathrine Skarstein1,2, Lara Adnan Aqrawi3, Roland Jonsson4,5 and Janicke Cecilie Liaaen Jensen6, 1Gade Laboratorium for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway, 2Department of Pathology, Haukeland University Hospital, Bergen, Norway, 3Department of Clinical Science, University of Bergen, Bergen, Norway, 4Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, 5Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, 6Department of Oral Surgery and Oral Medicine, University of Oslo, Oslo, Norway

    Background/Purpose A positive salivary gland (SG) biopsy with a focus score of ≥1 is the only widely accepted pathological finding confirming the salivary gland component…
  • Abstract Number: 2929 • 2014 ACR/ARHP Annual Meeting

    Molecular Diagnostics for Patient Subsetting in Sjögren’s Syndrome

    John C. Hall1, Alan N. Baer1, Mi Y. Lam2, Lindsey A. Criswell3, Antony Rosen1 and Livia Casciola Rosen1, 1Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Orofacial Sciences, University of California San Francisco, San Francisco, CA, 3Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA

    Background/Purpose Sjögren’s syndrome (SS) is a chronic autoimmune disease which targets exocrine glands, particularly salivary and lacrimal glands.  While all SS patients have abnormal secretory…
  • Abstract Number: 2543 • 2014 ACR/ARHP Annual Meeting

    Anti-Ro/SSA Positive Incomplete Sjögren’s Syndrome

    R. Hal Scofield1, Anne Igoe2, Donald U Stone3, Lida Radfar4, Kimberly S. Hefner5, David M. Lewis6, Stephen Young6, Judy Harris7, Kiely Grundahl7, Biji T. Kurien8, Jacen Maier-Moore9, Kristi A. Koelsch10, James Chodosh11, Nelson L. Rhodus12, Raj Gopalakrishnan13, Barbara M. Segal14, A. Darise Farris15, Courtney G. Montgomery16, Christopher J. Lessard17, Kathy L. Sivils18 and Astrid Rasmussen7, 1US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 2Metro Health, Cleveland, OH, 3Dean McGee Eye Institute, Oklahoma City, OK, 4College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 5Hefner Eye Care and Optical Center, Oklahoma City, OK, 6College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 7Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 8U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, 9Dept. of Clinical Laboratory Science, University of Texas at El Paso, El Paso, TX, 10Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, 11Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, 12University of Minnesota, Minneapolis, MN, 13Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, 14Rheumatology, Hennepin County Medical Center, Minneapolis, MN, 15Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 16Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 17825 N.E. 13th St., Oklahoma Medical Research Foundation, Oklahoma City, OK, 18Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Sjögren’s syndrome (SS) is a systemic disease characterized by dry eyes and mouth resulting from immune mediated damage and dysfunction of the lacrimal and…
  • Abstract Number: 526 • 2014 ACR/ARHP Annual Meeting

    A Descriptive and Comparative Study of the Transcriptome from Salivary Exosomes of Sjögren’s Syndrome Patients Using RNA-Seq

    Alessia Gallo1, Mayank Tandon2, Shyh-Ing Jang3, Ana Paola Cotrim4 and Ilias Alevizos5, 1NIH, Bethesda, MD, 2Sjogren's Clinic, NIDCR, Bethesda, MD, 3Molecular Physiology and Therapeutics Branch, NIDCR, Bethesda, MD, 4NIDCR, NIH, Bethesda, MD, 5Sjogren's Clinic, NIDCR/ NIH #10 1N110, Bethesda, MD

    Background/Purpose Saliva is a biofluid secreted by the salivary glands (SGs) that is critical for the health of the oral cavity. In Sjögren’s Syndrome (SS),…
  • Abstract Number: 2932 • 2014 ACR/ARHP Annual Meeting

    Increased Risk of Deep Vein Thrombosis and Pulmonary Embolism in Sjögren’s Syndrome: A General Population-Based Cohort Study

    Marko Yurkovich1, Hyon K. Choi2, Eric C. Sayre3, Kamran Shojania4 and J. Antonio Avina-Zubieta5, 1Department of Medicine, University of British Columbia, Vancouver, BC, Canada, 2Boston University School of Medicine, Boston, MA, 3Arthritis Research Centre of Canada, Richmond, BC, Canada, 4Rheumatology, University of British Columbia, Vancouver, BC, Canada, 5Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada

    Background/Purpose: There is limited data available on the risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) in Sjögren's Syndrome (SjS). We estimated the…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology